FDA
-
-
-
-
-
-
-
Tissue Dynamics partners with Galmed to develop cardiac fibrosis platform
-
-
-
-
-
-
-
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
-
-
-
-
-
-
-
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
-
-
-
-
-
-
-
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
-
-
-
-
-
-
-
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
-
-
-
-
-
-
-
Galmed Pharma (GLMD) Receives Nasdaq Non-Compliance Notice
-
323,584 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

